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Abstract: Cytochrome P4501A1 (CYP1A1), an enzyme known to metabolize polycyclic aromatic hydrocarbons, is regu-
lated by the aryl hydrocarbon receptor (AhR). The involvement of protein kinase C (PKC) in the regulation of AhR signal 
transduction pathway, has been widely studied but the role of specific PKC isoform(s) involved in this process it is not 
well clarified. To study which PKC isoform(s) is implicated in the regulation of CYP1A1, in the poorly tumorigenic 
MH1C1 rat hepatoma cells, we examined the effects of some PKC pharmacological inhibitors, Calphostin C (CAL), 
Staurosporine (STA) and H7, and of 12-0-tetradecanoyl phorbol 13-acetate (TPA), a PKC activator, on basal and 3-
methylcholanthrene (MC)-induced CYP1A1 protein expression and mediated ethoxyresorufin O-deethylation (EROD) ac-
tivity. In parallel, the activities of PKC-, -I, - and - isoforms, the most expressed in MH1C1 cells, were monitored. 
After pre-treatment with CAL, STA and H7, the MC-induced CYP1A1 protein and EROD activity were rapidly reduced 
with temporal profile similar to the profile of the activity of  and 1 PKC isoforms. Moreover, TPA pre-treatment in-
duced a biphasic effect on EROD activity, and a decline of PKC - I and -, in first instance, and - and - activities later 
on. These findings clearly show that, in MH1C1 cells, PKC is involved in CYP1A1 regulation and that  and I classic 
PKC isoforms play an active role in modulating this process. 
Key Words: CYP1A1, PKC, TPA, PKC inhibitors, rat hepatoma cell line, in vitro.  
INTRODUCTION 
 Among cytochrome P450s (CYPs) one of the most 
widely studied is the CYP1A1 isoenzyme, that despite its 
low expression level in many tissues, is highly inducible by 
polycyclic aromatic hydrocarbons (PAHs) and is able of bio-
activating a large number of xenobiotics to toxic derivatives 
[1-4]. 
 Mechanisms of CYP1A1 induction by the products of the 
aryl hydrocarbon (Ah)-inducible gene battery, have been 
widely studied, as reviewed by Whitlock in 1999 [5]. Ah-
receptor (AhR) is a member of the basic helix-loop-helix / 
Per-Arnt-Sim (bHLH/PAS) family of transcription factors 
[6]. Unliganded AhR exists in a complex with heat shock 
protein 90 (HSP90), the HSP90 co-chaperone p23, and a 
hepatitis B virus X-associated protein 2 (XAP2) in the cyto-
plasm [7-10]. Upon ligand binding, i.e. PAH, activated AhR 
is translocated from the cytoplasm into the nucleus where 
dimerizes with AhR nuclear translocator (Arnt). The AhR/ 
Arnt heterodimer binds to a specific DNA element termed 
the xenobiotic response element (XRE), in the transcriptional 
regulatory region to regulate the transcription of AhR target 
genes including CYP1A1, CYP1A2, CYP1B1, and AhR 
repressor genes [11-13] . 
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 Since AhR and Arnt are both phosphorylated on threo-
nine residues, it was suggested that serine/threonine kinases 
may be directly or indirectly involved in the functional regu-
lation of these proteins. Variety of data obtained from in 
vitro experiments, whole-animal studies, and eukaryotic cell 
culture experiments have demonstrated that the serine/ 
threonine kinase PKC plays an important role in the  
regulation of the AhR signal transduction pathway, and its 
activity is required for nuclear events in the CYP1A1 tran-
scriptional pathway [14-20]. 
 PKCs are a family of homologous enzymatic isoforms 
implicated in a wide range of cellular functions, being in-
volved in the transduction of signals for cell proliferation, 
differentiation and apoptosis. PKC isoforms are broadly sub-
divided into three subfamilies: classical (cPKC,, , , ), 
calcium (Ca
2+
) dependent and stimulated by second messen-
ger diacylglycerol (DAG); novel (nPKC, , ,  and ) Ca2+ 
independent but stimulated by DAG; and atypical (aPKC, ,  
and 	) which require neither Ca2+ nor DAG for optimal ac-
tivity [21]. PKC role in CYP induction is not clearly ex-
plained but several studies, however, have revealed that 
AhR-dependent and PKC-directed induction of CYP1A1 and 
CYP1A2 genes exist, with differences regarding cell type and 
tissue [14, 22, 23] and consequently, it is possible to hy-
pothesize a cell type related expression of the dioxin-
responsive genes. Further investigations have demonstrated 
that PKC activity is required for AhR-mediated signal trans-
duction [18, 24, 25] in order to influence the receptivity of 
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AhR to ligand and /or the entry of liganded AHR into the 
nucleus [5, 7, 26]. Moreover, the differences in such re-
sponses might be also due to differential expression of PKC 
isoforms in various tissues [27]. 
 An in vitro study has reported a stimulation of 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) mediated induction of 
CYP1A1, when PKC was activated by phorbol esters, and a 
suppression of TCDD-mediated induction of CYP1A1 [18], 
after exposure to Staurosporine (STA), a PKC-inhibitor. 
Moreover, Machemer and Tukey (2005) demonstrated that a 
dose-dependent inhibition of PKC activity by Staurosporine 
was concordant with inhibition of TCDD-induced CYP1A1-
luciferase activity and although, in the same study, some 
PKC inhibitors such as GF109203X, Gö 6983, and Gö 6976, 
blocked PKC activity at concentrations independent of those 
necessary to inhibit TCDD induction of CYP1A1-luciferase 
activity, it has clearly shown the involvement of PKC at 
some level of the pathway and how the effect can be isoform 
specific [28]. 
 Taken together, these findings do not clarify whether 
PKC direct interaction (i.e, PKC phosphorylates the AhR 
and/or CYP1A1 directly), or whether PKC-mediated phos-
phorylation of another intracellular signaling components led 
to an indirect induction on CYP1A1. Several studies indicate 
that PKC plays an important role in cellular communication 
by relaying signaling events upstream of phospholipid hy-
drolysis to downstream kinases such as MAP kinase and AP-
1 complex. Interactions between MAP kinase activity and 
regulation of the AhR-Arnt heterodimer complex - CYP1A1 
induction [29-34] have been reported and AP-1 activity has 
been shown to be induced by AhR ligands [35, 36]. 
 In our previous papers, we demonstrated that the well 
differentiated, poorly tumorigenic MH1C1 rat hepatoma cell 
line is highly responsive to classical CYP1A1 inducers [37-
39], such as 3-methylcholanthrene (MC); it was also re-
ported that MH1C1 cells express PKC-, -, - and - iso-
forms, and that their proliferation rate is PKC- and not 
PKC--dependent [40, 41]. 
 Aim of present study is to verify basal and MC-induced 
CYP1A1 protein expression and catalytic activity in MH1C1 
cells, after exposure to some pharmacological inhibitors for 
PKC, such as STA, a broad spectrum PKC inhibitor, Cal-
phostin C (CAL), an inhibitor of PKC-, - and -, H7, a 
PKC- inhibitor, and to 12-O-Tetradecanoyl phorbol 13-
acetate (TPA), a protein kinase C activator. Furthermore, to 
determine which isoform(s) of PKC could be involved in the 
regulation of AhR signaling pathway, we have monitored the 
protein expression levels and activities of most expressed 
PKC isoforms, -, -, - and -, during CYP1A1 induction.  
MATERIALS AND METHODOLOGY 
Chemicals 
 Culture medium (Dulbecco’s modified Eagle’s/Ham’s 
F12, 1:1, DMEM/F12), fetal bovine serum (FBS), trypsin-
EDTA and saline solutions, neutral red, dimethyl sulfoxide 
(DMSO), MC, CAL, STA, H7, TPA, 7-ethoxyresorufin, di-
cumarol, -glucuronidase/arylsulphatase (Type I), -mercap- 
 
toethanol, leupeptin, phenylmethylsulphonylfluoride (PMSF) 
were purchased from Sigma Aldrich (Milan, Italy); PVDF 
membranes (Hybond-P), Enhanced Western Blotting Analy-
sis System (ECL) and polyclonal secondary antibodies were 
supplied by GE Healthcare (Amersham, Bucks, U.K.). Poly-
clonal antisera specific for PKC isoforms were from Santa 
Cruz Biotechnology, (Santa Cruz, CA, USA). Anti-CYP1A1 
antibody was obtained by OXYgene (Dallas, TX, USA). 
Bradford reagent dye concentrate was obtained from Bio-
Rad (Hercules, CA). All other chemicals and reagents were of 
the highest purity available and were purchased from Merck 
(Darmstadt, Germany). 
CELL LINE 
 The rat hepatoma cell line MH1C1, obtained from Intelab 
Cell Line Collection (ICLC, IST, Genoa, Italy) was main-
tained in DMEM/F12(1:1) medium supplemented with 7% 
FBS in a humidified atmosphere with 5% CO2. The medium 
was changed every 2-3 days. The cells were subcultured by 
trypsin-EDTA treatment. The cell cultures, periodically che-
cked, resulted mycoplasma-free, using the DNA fluoro-
chrome staining method with bis-benzamide dye (Hoechst 
33258) and were at the 50-60 subcultures. 
CELL TREATMENTS 
 MH1C1 cells were seeded 24 hours before the treatments 









cells, respectively) for the evaluation in semi-confluent 
cultures of cytotoxicity, CYP1A1-mediated catalytic activity 
and immunoreactive proteins, respectively. Before addition 
to the serum-free medium, CAL, H7, STA, TPA and MC 
were dissolved in DMSO, which was at a final concentration 
not exceeding 0.2% (used in the solvent controls). To com-
pare the effects of the treatments in both basal and induced 
conditions, the cultures were exposed in triplicate for 2 hours 
to CAL, STA and H7 at various concentrations, whereas the 
treatment with 100 nM TPA lasted 1, 6, 9, 12 and 24 hours, 
and then exposed for further 24 hours to DMSO alone or to 
the CYP1A1 inducer 10 μM MC, dissolved in the medium 
still containing the previous compounds. 
CELL VIABILITY  
 In order to define the non toxic concentration for each 
chemical compound, cell viability was assessed by means of 
the neutral red uptake (NRU) assay, according to the method 
of Borenfreund et al. [42]. After incubation for 3 hours at 
37°C in a neutral red dye containing medium (50 μg/ml), the 
cells were washed twice in PBS solution and fixed by the 
procedure described by Riddell et al. [43]. The plates were 
then left at room temperature for 10 min and the absorbance 
of the extracted neutral red dye was read at 550 nm in a 
Uniskan II microplate reader (Labsystems, Helsinki, Fin-
land). 
PROTEIN DETERMINATION 
 Protein content of cell lysates was determined by the Bio-
Rad reagent protein assay [44], using bovine serum albumin 
as standard. 
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CYP1A1 CATALYTIC ACTIVITY 
 The CYP1A1-dependent 7-ethoxyresorufin O-deethylase 
(EROD) activity was determined by a fluorometric assay 
[45], with minor modifications as described elsewhere [39]. 
After experimental treatments, monolayers were exposed for 
1 hour to a serum-free culture medium containing 10 M 
dicoumarol and 8 M ethoxyresorufin; after hydrolysis of 
resorufin-conjugates with -glucuronidase/arylsulphatase 
and extraction with methanol, the fluorescence was meas-
ured using a Perkin-Elmer LS-5 (Beaconsfield, UK) spectro-
fluorometer with excitation and emission wavelengths of 530 
and 585 nm, respectively. The level of resorufin was evalu-
ated by comparison with a standard solution and expressed 
as pmol/min/mg protein. 
TOTAL CELL LYSATE 
 After removal of the experimental medium, the monolay-
ers were washed twice with cold Hank’s balanced solution, 
and scraped in cold lysis buffer (10 mM HEPES, pH 7.5, 
0.25 M sucrose, 5 mM EDTA, 10 mM -mercaptoethanol , 2 
mM PMSF , 1 mM leupeptin and 0.2 % Triton X-100). Cell 
suspensions were incubated for 25 min at 4°C prior to soni-
cation at 50 W for 10 sec. Lysates were then centrifuged at 
100,000 x g for 30 min and collected supernatants were 
stored at -80°C for up to 7 days. 
WESTERN BLOT ANALYSIS 
 Cell lysate proteins (50 μg) were resolved on SDS-PAGE 
gels in a Mini-protean II Electrophoresis Cell (Bio-Rad), and 
electroblotted onto a Hybond membrane, according to the 
manufacturer (GE Healthcare). Blots were probed with each 
primary antibodies, followed by exposure to horseradish 
peroxidase-conjugated secondary antibody. The immunore-
active proteins were visualized using ECL detection reagent, 
according to the manufacturer’s protocol. The intensities of 
the protein bands were analysed by densitometric analysis 
(Gel Doc 2000, Bio-Rad), followed by quantitation with 
Quantity One (Bio-Rad) software. 
PKC ACTIVITY ASSAY 
 Classic and novel PKC isoforms were immunoprecipi-
tated with specific antibodies and protein G-sepharose start-
ing from 50 g of protein sample. The immunoprecipitates 
were washed three times in a PKC buffer (10 mM Tris HCl, 
150 mM NaCl, 10 mM MgCl2, and 0.5 mM DTT). The ac-
tivity assay of classic isoenzymes [46-48] was performed by 
adding 40 μl of PKC buffer supplemented with 0.1 mM 
ATP, [32P]ATP (2 μCi per sample), 1 μg of phosphatidyl-
serine, 0.4 μg of dioleilglycerol, 0.5 mM CaCl2, and 10 μg 
of histone H1 as substrate. The same reaction mixture with-
out calcium was used to evaluate the activity of novel PKCs. 
The reaction was continued for 10 min at 30°C, then stopped 
by addition of Laemmli sample buffer. After centrifugation, 
the reaction mixtures were loaded onto 12.5% SDS-
polyacrilamide gel, which was dried and then exposed to an 
autoradiographic film for 24 h. Relative intensity of phos-
phorylated substrates was measured by densitometric scan-
ning of autoradiographs. 
 
STATISTICAL ANALYSIS 
 Results are expressed as means ± SEM of at least three 
independent experiments performed in triplicate. Signifi-
cance was assessed by one-way analysis of variance 
(ANOVA) followed by Dunnet tests.  
RESULTS 
Effects of the MC Exposure on MH1C1 Cell Viability 
and EROD Activity 
 The 24 hours cell treatment with increasing MC-
concentration doses (from 1 to 10 M) did not show any 
significant impairment in cell viability, whereas EROD ac-
tivity was significantly increased in a dose-dependent man-
ner (Fig. 1, panel A). CYP1A1 induction after 24 hours 
treatment with 10 M MC, the concentration which gives the 
highest EROD specific activity levels without affecting vi-
ability, was confirmed by immunoblotting analysis of the 
protein level (Fig. 1, panel B). 
Evaluation of the Cytotoxicity After Pre-Treatments with 
PKC Inhibitors and TPA  
 To evaluate the implication of PKC in AhR-dependent 
CYP1A1 induction, 2 hours pre-treatments with PKC inhibi-
tors were performed. In order to be sure that the results ob-
tained were due to PKC-dependent pathway inhibition or 
modulation and not to cytotoxic effects of the treatments, a 
careful choice of the concentration to use in the following 
experiments was done after evaluation of cell viability dur-
ing exposure to increasing concentration of PKC inhibitors 
(Table 1).  
 Although, in some conditions, the cell viability decreased 
significantly , we considered cytotoxic only those concentra-
tions able to decrease cell viability below 15% from the 
mean of all controls, as recommended by ECVAM (Euro-
pean Centre for the Validation of Alternative Methods, 
http://ecvam.jrc.it/).  
 Pre-treatments with CAL and STA reduced the cell vi-
ability by 14% and 12%, but the values at the highest con-
centration (100 nM) or in association with MC were always 
within the range of tolerance and therefore not considered 
cytotoxic. 
 H7 was cytotoxic at micromolar concentration with 21% 
and 32% reduction of cell viability, when used alone or in 
association with MC, respectively.  
 Cell exposure to TPA alone at the concentration range of 
1 - 100 nM did not reveal any cytotoxic effects (data not 
shown). 1, 6, 12 and 24 hours pre-treatments with 100 nM 
TPA followed by exposure to solvent (control) or 10 M MC 
for 24 hours did not exert cytotoxicity effects (Table 2) since 
cell viability never dropped below 88% .  
Effects of PKC Inhibitors on CYP1A1 Induction in 
MH1C1 Cells 
 Pre-exposure to different concentrations of PKC inhibi-
tors did not influence basal EROD activity (Fig. 2, panel A),  
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but when pre-treatments with STA, H7 and CAL were fol-
lowed by 24 hours MC exposure, EROD activity was inhib-
ited in a dose-dependent manner. Maximum concentrations 
equal to 100 nM, 75 nM and 50 μM for CAL, STA and H7, 
respectively, were chosen to carry out the experiments, in-
consequence of their ability to give a significant activity in-
hibition (88, 24 and 55 % reduction versus MC-treated cul- 
tures, respectively) together with a lower rate of cytotoxicity 
(85% of viability). 
 Inhibition of CYP1A1 induction, measured by EROD 
activity, was confirmed at protein level with immunoblotting 
experiments where the inducible expression level of the 
P450’s isoenzyme was measured in basal and induced condi-
tions with or without inhibitors. MC-treated cells clearly 
showed a decrease in protein expression level after pre-
treatment with PKC inhibitors, and in particular after CAL 
exposure (67% reduction) (Fig. 2, panel B). 
Effects of TPA on CYP1A1 Induction in MH1C1 Cells 
 In MH1C1 cells 100 nM TPA pre-treatment did not re-
veal any significant effect on CYP1A1 basal activity, during 
the exposure time considered, 0-24 hours (Fig. 3, panel A). 
Interestingly, TPA exerted a biphasic effect on MC–induced 
EROD activity: the enzymatic activity was dramatically de-
creased after 6 hour treatment with 65% reduction versus 
control (MC-treated cultures, time 0), a slow recovery, after 
12 hours, (22 % reduction , versus control) and a stable pla-
teau between 12 and 24 hours treatment. A parallel pattern 
 was observed in CYP1A1 protein level by immunoblotting 
(Fig. 3, panel B). 
EFFECTS OF PKC INHIBITORS AND TPA ON 
KINASE ACTIVITY IN MC-TREATED CELLS 
 Western blotting analysis confirmed that PKC-
, , ,  isoforms are expressed in MH1C1 cell lines, 
and no statistically significant changes were observed after 
treatment with 10 μM MC (Fig. 4).  
 In order to identify which of these PKC isoforms is/are 
possibly involved in CYP1A1 AhR-dependent induction, in 
our in vitro model, we analyzed the activity of two classic ( 
and ) and two novel ( and ) PKC isoforms. All of them 
are responsive to TPA and to PKC inhibitors to different 
extent (Figs. 5 and 6). 
 The enzymatic activities of classic and novel isoforms 
evaluated by immuno-precipitation, showed that in MC-
treated cells, PKC- and  were more sensitive to inhibitor 
treatments with respectively 35 and 25% decrease of the 
activity in presence of CAL, 25 % (PKC-) and 19% (PKC-




















Fig. (1). Effects of MC exposure on MH1C1 cell viability and EROD activity. 
Data represent EROD activity (pmol/min/mg protein) in samples treated with different concentrations of 1-2.5-10 M MC, (panel A, left 
hand side) and the percentage of viability, extrapolated by NRU index, of MC treated samples versus DMSO, as un-induced control (panel A, 
right hand side). Values represent the means ± SEM of 4 separate experiments run in triplicate. *, significantly different (p<0.001) vs value 
un-induced cultures (ANOVA test followed by Dunnett’ post hoc test). Panel B, the immunoblots shown originate from one representative 
experiment of CYP 1A1 protein induction after 24 h treatments with DMSO (control solvent) and 10M MC. For further details, see Materi-
als and Methodology.  
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Table 1. Cytotoxicity of PKC Inhibitors on MH1C1 Rat Hepatoma Cells 
PKC  
Inhibitor 
Conc  Un-Induced MC - Induced 




1 nM  




100 ± 0.5 
96 ± 0.9 
93 ± 1.5 
91 ± 1.8 
90 ± 1.1 
89 ± 2.  
98 ± 1.21* 
88 ± 1.6* 
87 ± 0.9* 









100 ± 0.3 
99 ± 2.0 
98 ± 4.0 
97 ± 0.8 
88 ± 1.8* 
98 ± 2.3 
97 ± 2.1 
96 ± 0.8 
96 ± 0.7 









100 ± 0.5 
98 ± 1.0 
96 ± 0.7 
93 ± 1.1* 
79 ± 1.2* 
99 ± 1.0 
92 ± 1.8 
89 ± 1.3* 
85 ± 2.1* 
68 ± 1.4* 
MH1C1 cells were exposed to PKC inhibitors, CAL, STA and H7, for 2 hours and then for further 24 h to solvent alone (un-induced) or 10 μM MC. Data are expressed as percentage 
of viability extrapolated by NRU index, versus untreated control cultures. Values represent the means ± SEM of 4 separate experiments run in triplicate.  
*, significantly different (p<0.001) vs un-induced cultures (ANOVA test followed by Dunnett’ post hoc test). For further details, see Materials and Methodology. 
 
Table 2. Time Dependent Effects of TPA Exposure on Viability of MH1C1 Rat Hepatoma Cells 
Time Exposure (Hours) Un-Induced MC - Induced 
0 100 ± 0.5 98 ± 1.2  
1 98 ± 0.2 97 ± 0.8 
6 97 ± 1.1  95 ± 1.9* 
12  95 ± 1.5*  89 ± 1.2* 
24  92 ± 1.8*  88 ± 0.5* 
MH1C1 cells were exposed to TPA for 1-6-12-24 hours and then for further 24 h to DMSO alone (un-induced) or 10 μM MC. Data are expressed as percentage of viability extrapo-
lated by NRU index, versus untreated control cultures. Values represent the means ± SEM of 4 separate experiments run in triplicate. 
*, significantly different (p<0.001) vs value un-induced cultures (ANOVA test followed by Dunnett’ post hoc test). For further details, see Materials and Methodology.  
 
(PKC-)  reduction after pre-treatment with H7. PKC- and 
, instead, were not deeply affected by any of the treatments. 
  The PKC activity was also measured in the presence of 
TPA, a well known tumoral promoting agent. As shown in 
Fig. 6, TPA induced time-related variations of classic and 
novel PKC isoform activities. Three hours pre-treatments 
with TPA decreased PKC- and -I activity by 60%. After 6 
hours PKC- was still inhibited to the same extent, whereas 
I activity recovered, reaching 78% of the control value 
(time 0). After 9 hour incubation PKC- activity increased, 
reaching 70% of the control value (time 0) while I main-
tained the same level. PKC- and - activities were affected 
only after 6 hour pre-incubation with TPA, with a quick re 
covery of PKC- after 9 hours of treatment, whereas PKC- 





 Exposure to environmental contaminants, such as PAHs, 
leads to induction of cytochrome P450 1A1 and 1A2 [49-
55]. The process of transcriptional activation of these cyto-
chromes involves different steps and proteins as a result of a 
ligand dependent activation. Among the different signaling 
process involved it is well known that PKC plays a role, al-
though neither the mechanism nor the role of the different 
isoforms are completely understood. 
 MH1C1 rat hepatoma cells represent a useful in vitro 
model because of their well-differentiated phenotype, and for 
their high responsiveness to classical CYP1A1 inducers [39, 
56]. In this paper EROD activity specific to CYP1A1 [57] is 
evaluated in this cell line in basal and MC-induced condi-
tions, and in the presence of TPA and PKC inhibitors; in 
parallel, the activities of PKC, ,  and - isoforms are 
monitored. 
 






















Fig. (2). Effects of PKC inhibitors on CYP1A induction in MH1C1. 
Panel A: data represent EROD activity (pmol/min/mg protein) in samples treated for 2 hours with different concentrations of PKC inhibitor 
and for the last 24 hours in presence of solvent alone (un-induced) or 10 mM MC (empty dots). Values represent the means ± SEM of 4 sepa-
rate experiments run in triplicate. Panel B:  On the left:  the immunoblots shown originate from one representative, of  5 similar experiments,   
of CYP 1A1 protein induction after pre-treatment with 100 nM CAL, 75 nM STA and 50 μM H7 and for the last 24 hours in presence of sol-
vent (un-induced)  or  10 μM MC.  On the right:   the respective densitometric analysis of CYP1A1  protein. Data are expressed as means ± 
SEM of 5 separate experiments; GAPDH was analysed as housekeeping gene. *, § p<0.001 vs respective un-treated  control cultures and MC 















Fig. (3). Effect of TPA on CYP1A1 induction in MH1C1. 
Panel A: data represent CYP 1A1 specific activity (EROD) (pmol/min/mg protein) in samples treated with 100 nM TPA alone for 0-1-6-12-
24h and for the last 24 hours in presence of solvent (un-induced, (full dots)), or 10 mM MC (empty dots). Values represent the means ± SEM 
of 4 separate experiments run in triplicate. Panel B: The figure depicted represents the immunoblots shown originate from one representative 
experiment, of 5 similar experiments, of CYP 1A1 protein level in the same experimental conditions described above. In the lower part it was 
reported the respective densitometric analysis of CYP1A1 protein; GAPDH was analysed as housekeeping gene Data are expressed as means 
± SEM of 5 separate experiments. *, § p<0.001 vs respective un-treated control cultures and MC alone-treated cultures, respectively (test 
ANOVA followed by Dunnett's test). For further details, see Materials and Methodology.  
 









Fig. (4). PKC-, -I. - and - protein levels in MH1C1 cells.  
Western blotting was performed to analyse PKC-, -, - and - isoform levels after 24h treatment with solvent alone (C) or with 10M MC. 
The immunoblots shown originate from one representative experiment among five independent experiments. Immunoreactive bands were 
quantified and the arbitrary units of all by densitometric analysis and normalized to GAPDH levels, and no significant differences were evi-























Fig. (5). PKC isoform activity in MH1C1 cells after exposure to PKC inhibitors and MC. 
MH1C1 cell cultures were exposed to 10 μM MC, for the last 24 hours, alone or after 2 hours pre-treatment with 100 nM CAL, 75 nM STA 
and 50 μM H7. Classic ( and I, Panel A and B , respectively) and novel ( and ,  panel C and D , respectively ). PKC isoenzymes were 
immuno-precipitated by specific antibodies and their enzymatic activities were assayed with H1 histone as substrate. Proteins were separated 
by SDS-PAGE, and H1 histone phosphorylation was detected by autoradiography. The autoradiograms shown, originate from one representa-
tive experiment. Phosphorylation of the substrate by PKC isoforms was quantified by densitometric analysis. The graph reports the arbitrary 
units of PKC isoenzyme activity expressed as mean ± SEM of three separate experiments.  
*, significantly different (p<0.001) vs value MC-induced cultures (ANOVA test followed by Dunnett’ post hoc test).  
 The decrease in MC-induced EROD activity in presence 
of CAL, STA and H7 has been confirmed at the protein level 
with a clear inhibition of CYP1A1 at the concentrations of 
the inhibitors which modulate the kinase activity without 
toxic effects on the cells. These observations are consistent 
with many studies in the last decade which have reported the 
modulation mediated by PKC of CYP1A1 activity and ex-
pression in many cell types and tissues. A various number of 
data and papers on in vitro and in vivo studies suggest that 
serine/threonine kinase PKC plays an important role in the 
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regulation of AhR signal transduction pathway [14, 15, 23, 
25, 58, 59]. 
 Our findings indicate an involvement of PKC in CYP-
1A1 induction by MC, since pre-treatments with PKC inhibi-
tors clearly abrogated CYP1A induction at the activity and 
protein level. Treatments with TPA show suppression of 
MC-induced CYP1A1, with a significant reduction of EROD 
specific activity in cells pre-treated for 6 hours with 100 nM 
TPA prior MC addition (Figure 3, panel A). However, the 
level of reduction is time-dependent. In fact, after 12 hours 
the activity recovers by reaching 78% of value of the control 
(MC treated, time 0) and remains constant up to 24 hours. 
The biphasic effect of TPA on MC-induced CYP1A, was 
already demonstrated by Moore et al. [58] who found that 
TPA causes a time and concentration-dependent modulation 
of TCDD-induced CYP1A1 gene expression in MCF-7 cells. 
 The mechanism by which PKC is able to mediate CYP 
induction through AhR mediated signal transduction has 
been extensively studied [15, 18, 24, 28, 60], and although 
significant contributions have made towards understanding 
this process, little is known about which specific PKC iso-
forms are involved in this process. 
 Analyzing data relative to down-regulation of CYP1A1 
induction in the presence of PKC inhibitors and the activity 
of single isoenzymes, it is evident that CAL, counteracting 
CYP induction, causes a significant reduction in the activitys 
of  and I isoforms of PKC (Fig. 5), thereby suggesting a 
possible involvement of classic PKC isoforms in the 
CYP1A1 regulation. 
 STA is less efficient in down-regulating PKC isoforms 
probably due to the lower specificity compared to other in-
hibitors. However, STA has been already shown to inhibit a 
variety of other kinases as well as PKC, including tyrosine 
kinases, protein kinase A, protein G, and calcium-calmodulin 
kinase [61-63]. Since after pre-treatments with PKC inhibi-
tors, MC-induced EROD activity decreases in a dose- de-
pendent manner, these data suggest a possible involvement 
of PKC or other STA-sensitive kinases in this process. 
 In our conditions we found an unresponsiveness of PKC-
 and - isoforms to any of the inhibitors tested; these results, 
























Fig. (6). PKC isoform activity in MH1C1 cells in presence of TPA and MC. 
Cells were pre-treated with TPA for 0-1-3-6 and 9 hours and MC was added for the last 24h of incubation. Classical ( and I. Panel A and B 
respectively ) and novel ( and ,  Panel C and D respectively ) isoenzymes were immuno-precipitated by specific antibodies and their enzy-
matic activities were assayed with H1 histone as substrate. Proteins were separated by SDS-PAGE, and H1 histone phosphorylation was de-
tected by autoradiography. The autoradiograms shown originate from one representative experiment. Phosphorylation of the substrate by 
PKC isoforms was quantified by densitometric analysis. The graph reports the arbitrary units of PKC isoenzyme activity expressed as mean ± 
SEM of three separate experiments.  
*, significantly different (p<0.001) vs value MC-induced cultures (ANOVA test followed by Dunnett’ post hoc test).  
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erly efficient to inactivate novel isoforms in MH1C1 cells 
and allow us to hypothesize a minor involvement of  and 
 isoforms in CYP1A1 induction. In this direction, Ma-
chemer and Tukey [28] compared dose-response curves of a 
luciferase CYP1A1 reporter gene with PKC isoform IC50 
values, in the presence of relatively specific inhibitors; they 
reported that treatments with Gö 6983 and GF109203X able 
to inhibit PKC- at different concentrations, did not block 
CYP1A1 luciferase activity and the inhibitor Gö 6976 able 
to block CYP 1A1 luciferase activity, did not inhibit PKC-
; moreover, inhibitors blocking PKC- activity, did not af-
fect CYP1A1 luciferase activity. Therefore, these data sug-
gest that PKC- and -  were not linked to regulation of 
CYP1A1 transcription. 
 TPA pre-treatment induced an early inhibition of CYP-
1A1 activity that is already appreciable after 1hour when 
PKC  is inhibited by 30%; moreover, after 6 hours TPA 
induced a maximal inhibition of CYP1A1 activity, determin-
ing at the same time a 65% decline in , 30% in  and 35% 
in  PKC activities (Figs. 4 and 6). It has been widely sup-
ported that treatment of cells with TPA, an activator of clas-
sic and novel PKC isozymes, leads to a plethora of responses 
in a strict cell-type-dependent specific manner [64]. In our 
context, the inhibition of MC–induced EROD activity is ob-
served at later times of TPA pre-treatments, when PKC iso-
forms, both classic and novel, are down-regulated as demon-
strated by the progressive loss of functional activities. In 
fact, TPA is able to induce translocation from cytosol to 
membrane and vice versa, and the down-regulation of PKC 
isoenzymes depends on the concentration and exposure time 
[65, 66]. 
 Recent studies with transfected NCI-H295 cells, point 
out a PKC involvement in controlling CYP11B2 gene ex-
pression. After treatments with GF109203X, a PKC inhibi-
tor, there was an increase in CYP11B2 promoter activity, 
whereas after TPA exposure the transcriptional activity was 
inhibited [67]. 
CONCLUSIONS 
 In summary this study shows that in MH1C1 cells PKC 
is involved in CYP1A1 regulation and that classic PKC iso-
forms are more likely to be an active part of this process. 
Our data show that CAL, which is more efficient in counter-
acting CYP1A1 induction, is able to inhibit  and   iso-
forms partially, and that TPA, which causes EROD activity 
inhibition, down-regulates PKC- and   probably as a con-
sequence of a quick activation of the kinases within few 
minutes, as also suggested by other studies [65-66]. Al-
though the delayed effect of TPA on PKC- and - doesn’t 
exclude a possible implication of these novel isoenzymes, 
we can confirm the potential role of PKC- and -I classical 
isoforms in the modulation of EROD activity, either through 
a direct action on CYP1A1 induction or via an indirect regu-
lation of MAPK pathways. This study represents an interest-
ing conceptual framework linking PKC mediated signal 
transduction to CYP1A1 induction, although further investi-
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ABBREVIATIONS  
AhR = aryl hydrocarbon receptor 
CAL = Calphostin C  
CYP = cytochrome P450 
EROD = 7-ethoxyresorufin O-deethylase 
MC = 3-methylcholantherene 
NRU = neutral red uptake test 
PAHs = polycyclic aromatic hydrocarbons  
PKC = protein kinase C 
STA = staurosporine 
TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin 
TPA = 12-O-tetradecanoyl phorbol 13-acetate  
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